Corcept Therapeutics Faces Class Action Lawsuits Over Alleged Securities Fraud in Drug Trials
- Corcept Therapeutics is facing class action lawsuits for allegedly misleading investors about relacorilant's drug trial and NDA status.
- The company received FDA warnings about its pivotal GRACE trial before stock fell 50.4% following a Complete Response Letter.
- Legal challenges emphasize the need for transparency and accountability from biopharmaceutical companies regarding their product candidate disclosures.
Corcept Therapeutics Faces Legal Challenges Over Misleading Drug Trial Information
Corcept Therapeutics Incorporated is currently embroiled in multiple class action lawsuits accusing the company of securities fraud, primarily related to its investigational drug, relacorilant, aimed at treating hypertension associated with hypercortisolism. The allegations point to a failure by the company to adequately disclose significant warnings from the U.S. Food and Drug Administration (FDA) regarding the design of its pivotal clinical trial, known as the "GRACE" trial. Investors, who purportedly incurred losses between October 31, 2024, and December 30, 2025, claim that Corcept misrepresented the status of relacorilant's New Drug Application (NDA) process, making positive statements that were ultimately misleading.
Throughout the class period, Corcept allegedly reassured its investors about the strength of its clinical data for relacorilant and the anticipated approval of the drug, despite receiving multiple warnings from the FDA highlighting potential issues with the evidence supporting the application. On December 31, 2025, the situation escalated when Corcept revealed it had received a Complete Response Letter (CRL) from the FDA, indicating that the agency could not make a favorable assessment of relacorilant's efficacy without additional evidence. Investors reacted swiftly to this news; the stock price plummeted from $70.20 to $34.80, a staggering 50.4% decline in value, resulting in a substantial market capitalization loss of nearly $2.5 billion.
The lawsuits highlight the importance of transparency and accurate communication from biopharmaceutical companies regarding their product candidates, particularly in light of active regulatory scrutiny. Legal firms such as Glancy Prongay Wolke & Rotter LLP and Robbins LLP are currently representing investors seeking lead plaintiff status before the April 21, 2026 deadline. As Corcept navigates these tumultuous waters, the outcomes of these legal challenges could significantly impact the company’s reputation and operational strategy in the competitive pharmaceutical landscape.
Additionally, Corcept faces heightened scrutiny from shareholders as they seek to hold the company accountable for the perceived negligence in its public disclosures. The results of the lawsuits may set a precedent regarding the responsibilities of pharmaceutical companies in maintaining investor relations and ensuring the accuracy of communications related to drug developments. With the pharmaceutical sector continually evolving, the outcomes of these lawsuits will be closely watched as they could influence future corporate governance practices within the industry.